sector medic suppli devic
 poor risk/reward cgm competit
heat initi coverag neutral
messag initi coverag neutral rate
bullish outlook cgm adopt abil sustain leadership
posit market time believ field enter disrupt phase spur
rapid influx new technolog feedback recent physician patient
survey suggest could risk share price perspect
process play someth believ fulli reflect stock
current level result prefer wait better entri point
believ continu glucos monitor cgm way becom
standard care insulin-depend diabet nearli year sinc
introduct countless studi valid advantag cgm tradit point-
in-tim blood glucos test reduc critic factor manag
diabet yet despit compel clinic evid support use penetr remain
rel low today type popul less
insulin-intens type patient mani factor contribut lacklust adopt
view includ inconsist sensor accuraci conveni qualiti life issu
high increment cost therapi recent advanc address mani
histor drawback technolog pave way increas penetr
undisput cgm leader today rapid pace innov
could prove disrupt view compani done get
cgm technolog today recent fda approv system
repres sixth platform iter past year along way compani
achiev mani notabl mileston includ last month becom
first cgm technolog compani garner fingerstick replac claim secur
medicar reimburs cgm competit landscap evolv rapidli howev
post recent fda approv abbott freestyl libr guardian connect
anoth one potenti way soon follow posit advisori panel
senseon eversens last week
feedback physician diabet patient suggest us
could risk new product roll libr particular repres
competit threat view low cost option appeal non-cgm user
exist custom either look cut expens burn inform
overload first full quarter market estim patient
prescrib libr put perspect math entir cgm market grew
patient recent survey high-volum endocrinologist
doc spoke forecast lose point market share
larg due inroad abbott see libr market expand technolog
well share taker convinc market growth acceler enough
accommod strong libr adopt street expect near-
term growth end spectrum also think investor overlook
senseon novel long-term implant sensor design recent survey type
diabet current cgm user said would either like
like tri eversens receiv fda approv
initi neutral view high-teen top-lin grower drop
low- mid-teen weather competit challeng
forecast could prove conserv underli cgm market growth exceed
expect also see increment downsid risk particularli price side
model modest pressur time share trade ntm sale
forecast follow recent recoveri believ stock offer favor
risk/reward investor take heighten uncertainti current level
prefer wait better entri point consid get posit name
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow last week fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
left right push button auto-appl touch screen receiv cgm sensor/transmitt
dexcom sale grown compound-annual-growth-rate sinc top last year
estim compani ship cgm sensor global
current instal base patient world-wide model call total
revenu climb compound-annual-growth-rate on-going cgm adopt type
diabet popul expand use among type patient partial off-set share
loss price pressur addit competitor enter market
figur revenu composit million
compani report guggenheim secur llc estim
page analyst certif import disclosur
clinic valu cgm proven numer studi insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
continu glucos monitor address shortcom smbg cgm system
use transcutan sensor test glucos level interstiti fluid skin
sensor worn bodi attach transmitt relay blood sugar
read handheld receiv and/or smartphon new read taken everi
minut throughout day provid patient near real-tim visibl
glucos level trend facilit better manag diseas cgm
util shown result greater decreas surrog measur
patient averag blood glucos level three month period smbg alon
figur show find independ type insulin deliveri multipl
daili inject insulin pump even small drop correl
signific reduct mani concomit risk factor associ diabet see
strong evid favor establish cgm standard care insulin-
figur summari cgm clinic efficaci result
view compani done advanc cgm technolog
nearli year sinc first introduc last week fda approv
new system mark compani sixth sensor iter past twelv year along
way earn high mark endocrinologist diabet patient
technolog custom servic recent conduct survey type
diabet util continu glucos monitor manag diseas within
sampl market share slightli share estim
compani hold overal cgm market ask respond number
question relat cgm experi includ overal satisfact level
sensor would choos opportun switch today case
score well earn highest custom satisfact score vs
abbott regist second highest percentag current
custom would opt stay compani given chanc switch vs
abbott importantli
guardian connect expect launch commerci later year survey
result reflect impact new technolog
page analyst certif import disclosur
see meaning step forward dexcom cgm portfolio system
featur number import advanc legaci includ elimin
requir daili fingerstick calibr issu acetaminophen interfer
also on-bodi footprint smaller come simpl
pushbutton auto-appl improv eas use sensor life also nomin extend
label day vs realiti though believ mani patient
alreadi stretch lifespan sensor day restart system
reach label end life model suggest averag custom
consum sensor equat day use per sensor
incorpor hard end life shut-off elimin opportun patient stretch
sensor beyond label
compani report fda summari safeti effect
perhap importantli accur sensor feasibl trial system
demonstr mean absolut rel differ mard data point
within either mg/dl refer test read mg/dl refer
read mg/dl view impress perform particularli
absenc daili calibr intend launch later
quarter june ada meet look us like logic venu product debut
meanwhil manag continu expect ce mark approv intern launch
later year
page analyst certif import disclosur
big question prepar launch opinion whether rich featur
set enough off-set mount competit pressur one topic
manag defer talk last week call price recent survey
high-volum endocrinologist physician identifi cost patient
impedi broader cgm adopt today price sensor
per day label support roughli howev discuss earlier
patient actual wear sensor day put realiz cost
closer result think like hold asp flat
shift exact de facto price increas custom
figur impedi increas cgm adopt
topic price particularli german moment given abbott recent
launch freestyl libr flash glucos monitor system libr isnt true cgm
although sensor take blood glucos measur everi minut data
transmit patient swipe reader sensor result libr
proactiv alert patient cross certain threshold key featur
tradit cgm system take ad import patient frequent
hypoglycem excurs parent tri keep track child glucos level
throughout day see signific limit cgm user need
alert alarm recent patient survey user said alerts/alarm
either unimport somewhat import diabet manag
physician spoke rank inform fatigu impedi broader
cgm adopt libr also featur could appeal patient includ
day sensor life calibr fingerstick requir make dose decis
libr disrupt featur howev abbott price strategi
technolog sensor retail vs recharg reader year
life goe separ transmitt buy result
prospect user trial libr without insur coverag less
theyr respons deduct co-pay compar all-in cost
start cours full year monitor estim libr cost
compar assum averag sensor life
day patient would respons portion all-in cost
depend insur coverag believ differ still meaning enough
matter mani custom
page analyst certif import disclosur
figur annual cgm therapi comparison vs libr
compani report guggenheim secur llc estim
physician view libr answer appear depend part
patient ask survey respond view libr compar
dexcom treatment option varieti popul rate decis
better pediatr type patient margin type adult meanwhil
libr seen superior option type adult patient slightli inferior
pediatr type popul agre libr potenti open type
opportun time abbott estim patient prescrib libr
date type
figur physician percept libr vs
see concern data point script data suggest
abbott ad roughli new patient first quarter follow decemb
launch put perspect estim entir cgm market ad
patient last year even assum larg percentag libr
patient smbg convert rather competit cgm win libr
patient eventu graduat full cgm system get comfort
process real-tim monitor still isnt clear us enough patient
satisfi libr earli adopt curv street expect near-term
page analyst certif import disclosur
libr isnt competit threat face moment medtron
recent receiv fda approv guardian connect first stand-alone cgm offer
outsid sensor-aug pump busi dont view guardian connect
par technolog sens continu priorit
pump franchis on-going roll-out still introduc addit competitor
segment market repres dexcom instal base today
five month ago
figur pictur cgm competit landscap
compani report guggenheim secur llc estim
elsewher follow posit advisori panel meet last week expect
senseon receiv fda approv eversens long-term implant sensor
sometim next month see eversens intrigu technolog one
could signific appeal patient dont want deal swap
sensor weekli appreci ad flexibl transmitt easili
taken necessari reappli packag becom
interest view senseon success extend sensor life day
alreadi approv europ eventu full year monitor singl
insert develop recent patient survey current cgm user
spoke said would either like like tri eversens meanwhil
endocrinologist queri estim current cgm patient would
consid switch indic would comfort perform
implant procedur proper train compani
page analyst certif import disclosur
challeng competit backdrop isnt stand still besid
recent approv compani work verili googl life scienc
research arm potenti disrupt new cgm system design goal
partnership develop sensor miniatur fulli dispos low cost
transmitt serv exist cgm market open new opportun
much larger non-intens type popul collabor agreement
issu stock verili august could owe anoth
mileston payment verili also entitl royalti product sale aris
agreement excess percentag start high-singl digit
declin mid-singl digit time
expect first verili product receiv fda approv soon
initi design intend proof concept revenu gener
howev margin profil wont allow wide commerci second
verili product fda approv expect encompass design
goal bandage-lik form factor also attract econom
believ type product could game changer manag diabet
point think still mani unansw question perform
launch time eventu go-to-market strategi assign valu
page analyst certif import disclosur
estim world-wide cgm market top grow
clip receiv fda approv first profession cgm system
effort recent confin promot cgm
adjunct featur insulin pump franchis develop sensor-
augment pump left non-pump segment market estim
account roughli third cgm patient meanwhil
think pump segment market split roughli
last year net result share posit cgm
figur estim cgm revenu market share geographi
compani report guggenheim secur llc estim
libr enter fray physician spoke expect lose
signific share overal respond forecast point share loss
abbott pick strength roll-out
page analyst certif import disclosur
abbott alreadi made impress gain intern libr launch late
sale top give abbott estim share ou cgm
market dollar basi closer term patient therapi addit
appeal featur technolog discuss import note libr
also benefit signific reimburs advantag europ tradit
cgm cover countri germani except payer much
quicker embrac lower cost flash glucos monitor option result dont
view intern libr experi good proxi could see domest
model call abbott gain point market share end
year overal patient instal base model gain come
evenli point point forecast
assum pace new libr patient addit actual slow
averag per quarter balanc year abbott experi
attrit rate vs also assum materi acceler
market growth net patient gain vs drive growth
 instal base
endocrinologist spoke also bullish potenti
increas adopt next year note group report
higher cgm penetr today within practic believ reflect
 market broadli adopt among type patient today vs
nationwid nonetheless view forecast cgm util rise adult
pediatr patient three year encourag data point
comparison model assum penetr climb
stori similar type side estim overal penetr stand
today vs respond report within insulin-intens
popul estim non-intens patient physician expect
cgm util among type patient practic climb
group respect compar forecast type
penetr rise insulin-intens popul estim dont current
alloc util non-intens group
page analyst certif import disclosur
model ww cgm revenu grow driven annual growth
patient instal base slower compound-annual-growth-rate market post
much explos growth driven libr rapid adopt
intern phenomenon dont expect repeat degre
assumpt patient instal base assum acceler gain
growth moder back back end
forecast period
compani report factset guggenheim secur llc estim
page analyst certif import disclosur
million use market market revenu growth medic suppli devic
diabet global epidem accord american diabet associ
american diabet popul preval
medicare-ag popul even higher rank seventh lead caus
death nationwid cite underli caus nearli case health
burden exert tremend financi toll total cost diagnos diabet
estim includ direct medic expens
lost product global world organ estim adult
diabet figur quadrupl sinc diseas contribut
death year
diabet patient typic broken two main subgroup type diabet
suffer underli immun disord caus bodi cell target
beta cell pancrea produc insulin caus condit unknown
believ deriv combin genet environment factor type
patient usual diagnos children ada estim roughli
type patient today cure type diabet patient
requir take lifelong regimen synthet insulin inject surviv
type diabet acquir metabol disord character increas insulin
resist although pancrea continu produc insulin total beta cell output may
also depress genet factor play role determin person suscept
type diabet usual caus obes lack exercis poor dietari habit
result treatment type diabet gener begin recommend lifestyl
chang unsuccess patient progress drug therapi eventu insulin-
intens treatment estim american suffer type
diabet insulin-depend
diabet number seriou health consequ without insulin bodi lose
abil regul blood sugar lead episod hyperglycemia high blood
glucos hypoglycemia low blood glucos hyperglycemia gener defin
blood glucos level mg/dl associ increas long-term risk
cardiovascular renal neurolog vision disord hypoglycemia mg/dl
acut issu brain requir continu suppli glucos function properli
earli symptom hypoglycem episod may includ dizzi confus rapid
heartrat treat lead seizur loss conscious even death
page analyst certif import disclosur
technolog effect manag diabet rapidli evolv insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
continu glucos monitor address shortcom smbg cgm system
use transcutan sensor test glucos level interstiti fluid skin
sensor worn bodi attach transmitt relay blood sugar
read handheld receiv and/or smartphon new read taken everi
minut throughout day provid patient near real-tim visibl
glucos level trend facilit better manag diseas
figur show exampl patient test four time cours
day two elev read two within normal rang figur
read overlaid cgm data show patient actual spent
vast major day outsid normal rang
page analyst certif import disclosur
